在性结肠炎中维多利祖马布持久性的长期结果和预测因素
Beatriz Gros1,2, Hannah Ross1, Maureen Nwabueze1
1Edinburgh IBD Unit, Western General Hospital, Edinburgh, Scotland, UK.
Therapeutic advances in gastroenterology
|August 1, 2024
概括
长期使用维多利祖马布 (VDZ) 对炎症性肠病 (IBD) 有效,显示持续临床缓解长达5年. VDZ的持续性取决于先前的先进疗法,基线类固醇使用和疾病程度.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在炎症性肠病 (IBD) 中,关于长期vedolizumab (VDZ) 结果的现实数据有限,特别是在一年以后.
- 很少有研究在长期VDZ治疗中评估了以前没有生物治疗的患者或客观炎症标志物.
研究的目的:
- 评估影响维多利祖马布 (VDZ) 持续性在IBD患者中的因素.
- 评估临床,生化和便生物标志物缓解率在1,3年和5年的VDZ治疗.
主要方法:
- 成年IBD患者接受VDZ诱导的回顾性观察队列研究.
- 通过电子医疗记录收集的数据,包括基线表型和后续信息.
主要成果:
- 在290名患者中,54.1%的患者在研究结束时仍在使用VDZ (平均随访时间为27.6个月).
- 更糟糕的VDZ持久性的预测因素包括先前的先进治疗,基线类固醇使用和广泛的疾病.
- 在1,3年和5年 (分别为75.7%,72.4%,70.2%) 观察到持续的临床缓解 (部分梅奥<2).
- 严重的不良事件发生率为每100个患者年中的1.2个.
结论:
- 维多利祖马布在IBD中表现出持久的有效性和有利的长期安全性.
- VDZ持久性受到先前的生物/小分子暴露,疾病分布和基线类固醇使用的显著影响.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Inflammatory Bowel Disease V: Surgical Management
138
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
138
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
Drugs for Treatment of Constipation-Predominant IBS
151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151


